新型β-内酰胺酶抑制剂纳库巴坦和齐他巴坦提高β-内酰胺类抗生素对脓肿分枝杆菌复合体临床分离株的活性。
New β-Lactamase Inhibitors Nacubactam and Zidebactam Improve the Activity of β-Lactam Antibiotics against Mycobacterium abscessus Complex Clinical Isolates.
机构信息
Center for Tuberculosis Research, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
出版信息
Antimicrob Agents Chemother. 2019 Aug 23;63(9). doi: 10.1128/AAC.00733-19. Print 2019 Sep.
Abstract
The new diazabicyclooctane-based β-lactamase inhibitors avibactam and relebactam improve the activity of β-lactam antibiotics against bacteria of the complex (MABC). Here, we evaluated the activities of two newer diazabicyclooctane-based β-lactamase inhibitors in clinical development, nacubactam and zidebactam, with β-lactams against clinical isolates of MABC. Both inhibitors lowered the MICs of their partner β-lactams, meropenem (8-fold) and cefepime (2-fold), respectively, and those of other β-lactams, similar to prior results with avibactam and relebactam.
摘要
新型的二氮杂二环辛烷类β-内酰胺酶抑制剂阿维巴坦和雷利巴坦提高了β-内酰胺类抗生素对复杂（MABC）细菌的活性。在这里，我们评估了两种处于临床开发阶段的新型二氮杂二环辛烷类β-内酰胺酶抑制剂纳库巴坦和齐他巴坦与β-内酰胺类药物对 MABC 临床分离株的活性。这两种抑制剂都降低了其β-内酰胺类药物（美罗培南（8 倍）和头孢吡肟（2 倍））的 MIC 值，以及其他β-内酰胺类药物的 MIC 值，这与阿维巴坦和雷利巴坦的先前结果相似。
相似文献
1
New β-Lactamase Inhibitors Nacubactam and Zidebactam Improve the Activity of β-Lactam Antibiotics against Mycobacterium abscessus Complex Clinical Isolates.新型β-内酰胺酶抑制剂纳库巴坦和齐他巴坦提高β-内酰胺类抗生素对脓肿分枝杆菌复合体临床分离株的活性。
Antimicrob Agents Chemother. 2019 Aug 23;63(9). doi: 10.1128/AAC.00733-19. Print 2019 Sep.
2
Activity of the New β-Lactamase Inhibitors Relebactam and Vaborbactam in Combination with β-Lactams against Mycobacterium abscessus Complex Clinical Isolates.新型β-内酰胺酶抑制剂雷利巴坦和沃巴坦与β-内酰胺类药物联合对脓肿分枝杆菌复合体临床分离株的活性。
Antimicrob Agents Chemother. 2019 Feb 26;63(3). doi: 10.1128/AAC.02623-18. Print 2019 Mar.
3
Multidrug-resistant Gram-negative clinical isolates with reduced susceptibility/resistance to cefiderocol: which are the best present and future therapeutic alternatives?对头孢地尔敏感性降低/耐药的多重耐药革兰氏阴性临床分离株：目前和未来最佳的治疗替代方案有哪些？
Eur J Clin Microbiol Infect Dis. 2024 Feb;43(2):339-354. doi: 10.1007/s10096-023-04732-4. Epub 2023 Dec 14.
4
In vitro effects of diazabicyclooctane β-lactamase inhibitors relebactam and nacubactam against three subspecies of Mycobacterium abscessus complex.二氮杂双环辛烷β-内酰胺酶抑制剂瑞来巴坦和那库巴坦对脓肿分枝杆菌复合群三个亚种的体外作用
Int J Antimicrob Agents. 2022 Nov-Dec;60(5-6):106669. doi: 10.1016/j.ijantimicag.2022.106669. Epub 2022 Sep 3.
5
Activity of cefiderocol and innovative β-lactam/β-lactamase inhibitor combinations against isogenic strains of Escherichia coli expressing single and double β-lactamases under high and low permeability conditions.头孢地尔肟与新型β-内酰胺/β-内酰胺酶抑制剂组合对高、低通透性条件下表达单种和双种β-内酰胺酶的同源大肠埃希菌的活性。
Int J Antimicrob Agents. 2024 May;63(5):107150. doi: 10.1016/j.ijantimicag.2024.107150. Epub 2024 Mar 19.
6
Impact of chromosomally encoded resistance mechanisms and transferable β-lactamases on the activity of cefiderocol and innovative β-lactam/β-lactamase inhibitor combinations against Pseudomonas aeruginosa.染色体编码耐药机制和可转移β-内酰胺酶对头孢地尔的活性及新型β-内酰胺/β-内酰胺酶抑制剂组合对铜绿假单胞菌的影响。
J Antimicrob Chemother. 2024 Oct 1;79(10):2591-2597. doi: 10.1093/jac/dkae263.
7
Potent β-Lactam Enhancer Activity of Zidebactam and WCK 5153 against Acinetobacter baumannii, Including Carbapenemase-Producing Clinical Isolates.Zidebactam 和 WCK 5153 对鲍曼不动杆菌的强效β-内酰胺增强活性，包括产碳青霉烯酶的临床分离株。
Antimicrob Agents Chemother. 2017 Oct 24;61(11). doi: 10.1128/AAC.01238-17. Print 2017 Nov.
8
In vitro activity of cefepime/zidebactam (WCK 5222) against Gram-negative bacteria.头孢吡肟/齐他西酮（WCK 5222）对革兰氏阴性菌的体外活性
J Antimicrob Chemother. 2017 May 1;72(5):1373-1385. doi: 10.1093/jac/dkw593.
9
Impact of relebactam-mediated inhibition of Mycobacterium abscessus BlaMab β-lactamase on the in vitro and intracellular efficacy of imipenem.雷巴他定对脓肿分枝杆菌 BlaMab β-内酰胺酶的抑制作用对亚胺培南体外和细胞内疗效的影响。
J Antimicrob Chemother. 2020 Feb 1;75(2):379-383. doi: 10.1093/jac/dkz433.
10
Impact of Acquired Broad Spectrum β-Lactamases on Susceptibility to Novel Combinations Made of β-Lactams (Aztreonam, Cefepime, Meropenem, and Imipenem) and Novel β-Lactamase Inhibitors in Escherichia coli and Pseudomonas aeruginosa.获得性广谱β-内酰胺酶对大肠埃希菌和铜绿假单胞菌中新型β-内酰胺类（氨曲南、头孢吡肟、美罗培南和亚胺培南）和新型β-内酰胺酶抑制剂组合药物敏感性的影响。
Antimicrob Agents Chemother. 2023 Jul 18;67(7):e0033923. doi: 10.1128/aac.00339-23. Epub 2023 May 31.
引用本文的文献
1
Novel C5α-substituted carbapenems enhance killing via selective target binding and reduced hydrolysis by Bla.新型C5α取代碳青霉烯类药物通过选择性靶点结合和降低Bla水解作用增强杀菌效果。
Antimicrob Agents Chemother. 2025 Aug 6;69(8):e0017025. doi: 10.1128/aac.00170-25. Epub 2025 Jun 17.
2
Durlobactam in combination with β-lactams to combat .杜洛巴坦与β-内酰胺类联合使用以对抗……
Antimicrob Agents Chemother. 2025 Feb 13;69(2):e0117424. doi: 10.1128/aac.01174-24. Epub 2024 Dec 23.
3
Durlobactam to boost the clinical utility of standard of care β-lactams against lung disease.杜洛巴坦可提高标准护理β-内酰胺类药物对肺部疾病的临床效用。
Antimicrob Agents Chemother. 2025 Jan 31;69(1):e0104624. doi: 10.1128/aac.01046-24. Epub 2024 Nov 20.
4
Dual β-lactams for the treatment of Mycobacterium abscessus: a review of the evidence and a call to act against an antibiotic nightmare.双重β-内酰胺类药物治疗脓肿分枝杆菌：对证据的回顾及对对抗抗生素噩梦的呼吁。
J Antimicrob Chemother. 2024 Nov 4;79(11):2731-2741. doi: 10.1093/jac/dkae288.
5
New Agents Are Coming, and So Is the Resistance.新的病原体正在出现，耐药性问题也随之而来。
Antibiotics (Basel). 2024 Jul 13;13(7):648. doi: 10.3390/antibiotics13070648.
6
effects of the new oral β-lactamase inhibitor xeruborbactam in combination with oral β-lactams against clinical isolates.新型口服β-内酰胺酶抑制剂头孢洛布坦与口服β-内酰胺类药物联合对临床分离株的作用。
Microbiol Spectr. 2024 Jul 2;12(7):e0008424. doi: 10.1128/spectrum.00084-24. Epub 2024 Jun 6.
7
Exploring antibiotic resistance mechanisms in for enhanced therapeutic approaches.探索[具体对象]中的抗生素耐药机制以改进治疗方法。 （你提供的原文“Exploring antibiotic resistance mechanisms in for enhanced therapeutic approaches.”中“in for”之间缺少具体内容，我根据语境补充了“[具体对象]”，你可根据实际情况调整）
Front Microbiol. 2024 Feb 6;15:1331508. doi: 10.3389/fmicb.2024.1331508. eCollection 2024.
8
Drugs for treating infections caused by non-tubercular mycobacteria: a narrative review from the study group on mycobacteria of the Italian Society of Infectious Diseases and Tropical Medicine.治疗非结核分枝杆菌感染的药物：来自意大利传染病和热带医学学会分枝杆菌研究组的叙述性综述。
Infection. 2024 Jun;52(3):737-765. doi: 10.1007/s15010-024-02183-3. Epub 2024 Feb 8.
9
Tackling Nontuberculous Mycobacteria by Repurposable Drugs and Potential Leads from Natural Products.利用可再利用药物和天然产物中的潜在先导化合物来应对非结核分枝杆菌。
Curr Top Med Chem. 2024;24(15):1291-1326. doi: 10.2174/0115680266276938240108060247.
10
Chemical genetic approaches for the discovery of bacterial cell wall inhibitors.用于发现细菌细胞壁抑制剂的化学遗传学方法。
RSC Med Chem. 2023 Aug 30;14(11):2125-2154. doi: 10.1039/d3md00143a. eCollection 2023 Nov 15.
本文引用的文献
1
Activity of New Tetracycline Analogs Omadacycline and Eravacycline against Drug-Resistant Clinical Isolates of .新型四环素类似物奥马环素和依拉环素对.耐药临床分离株的活性
Antimicrob Agents Chemother. 2019 May 24;63(6). doi: 10.1128/AAC.00470-19. Print 2019 Jun.
2
Dual β-Lactam Combinations Highly Active against Mycobacterium abscessus Complex .双联β-内酰胺组合对脓肿分枝杆菌复合体高度有效。
mBio. 2019 Feb 12;10(1):e02895-18. doi: 10.1128/mBio.02895-18.
3
Select β-Lactam Combinations Exhibit Synergy against .选择β-内酰胺类抗生素联合用药具有协同作用。
Antimicrob Agents Chemother. 2019 Mar 27;63(4). doi: 10.1128/AAC.02613-18. Print 2019 Apr.
4
Activity of the New β-Lactamase Inhibitors Relebactam and Vaborbactam in Combination with β-Lactams against Mycobacterium abscessus Complex Clinical Isolates.新型β-内酰胺酶抑制剂雷利巴坦和沃巴坦与β-内酰胺类药物联合对脓肿分枝杆菌复合体临床分离株的活性。
Antimicrob Agents Chemother. 2019 Feb 26;63(3). doi: 10.1128/AAC.02623-18. Print 2019 Mar.
5
Efficacy of Meropenem with a Novel Non-β-Lactam-β-Lactamase Inhibitor, Nacubactam, against Gram-Negative Organisms Exhibiting Various Resistance Mechanisms in a Murine Complicated Urinary Tract Infection Model.美罗培南联合新型非β-内酰胺类β-内酰胺酶抑制剂奈拉滨对抗具有多种耐药机制的革兰氏阴性菌在小鼠复杂性尿路感染模型中的疗效。
Antimicrob Agents Chemother. 2018 Aug 27;62(9). doi: 10.1128/AAC.02596-17. Print 2018 Sep.
6
Plasma and Intrapulmonary Concentrations of Cefepime and Zidebactam following Intravenous Administration of WCK 5222 to Healthy Adult Subjects.健康成年受试者静脉给予 WCK 5222 后头孢吡肟和齐多夫定的血浆和肺内浓度。
Antimicrob Agents Chemother. 2018 Jul 27;62(8). doi: 10.1128/AAC.00682-18. Print 2018 Aug.
7
Imipenem-Relebactam and Meropenem-Vaborbactam: Two Novel Carbapenem-β-Lactamase Inhibitor Combinations.亚胺培南-西司他丁钠和美罗培南-法硼巴坦：两种新型碳青霉烯-β-内酰胺酶抑制剂复方制剂。
Drugs. 2018 Jan;78(1):65-98. doi: 10.1007/s40265-017-0851-9.
8
Mycobacterium abscessus l,d-Transpeptidases Are Susceptible to Inactivation by Carbapenems and Cephalosporins but Not Penicillins.分枝杆菌 l,d-转肽酶对碳青霉烯类和头孢菌素类敏感，但对青霉素类不敏感。
Antimicrob Agents Chemother. 2017 Sep 22;61(10). doi: 10.1128/AAC.00866-17. Print 2017 Oct.
9
WCK 5222 (cefepime/zidebactam) antimicrobial activity tested against Gram-negative organisms producing clinically relevant β-lactamases.WCK 5222（头孢吡肟/齐地卡南）针对产生具有临床相关性β-内酰胺酶的革兰氏阴性菌的抗菌活性测试。
J Antimicrob Chemother. 2017 Jun 1;72(6):1696-1703. doi: 10.1093/jac/dkx050.
10
Combinations of avibactam and carbapenems exhibit enhanced potencies against drug-resistant Mycobacterium abscessus.阿维巴坦与碳青霉烯类药物联合使用对耐药脓肿分枝杆菌显示出增强的抗菌效力。
Future Microbiol. 2017 May;12(6):473-480. doi: 10.2217/fmb-2016-0234. Epub 2017 Feb 16.
Zotero 插件